| Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem … SK Kumar, SJ Jacobus, AD Cohen, M Weiss, N Callander, AK Singh, ... The Lancet Oncology 21 (10), 1317-1330, 2020 | 207 | 2020 |
| Targeting MCL-1 in hematologic malignancies: Rationale and progress AH Wei, AW Roberts, A Spencer, AS Rosenberg, D Siegel, RB Walter, ... Blood reviews 44, 100672, 2020 | 157 | 2020 |
| Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors THM Keegan, A Bleyer, AS Rosenberg, Q Li, M Goldfarb JAMA oncology 3 (11), 1554-1557, 2017 | 115 | 2017 |
| Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality A Brunson, A Lei, AS Rosenberg, RH White, T Keegan, T Wun British journal of haematology 178 (2), 319-326, 2017 | 107 | 2017 |
| Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute‐designated cancer centers in California G Ho, T Wun, L Muffly, Q Li, A Brunson, AS Rosenberg, BA Jonas, ... Cancer 124 (9), 1938-1945, 2018 | 49 | 2018 |
| Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM … S Kumar, SJ Jacobus, AD Cohen, M Weiss, NS Callander, AA Singh, ... J Clin Oncol 38 (18), 3, 2020 | 46 | 2020 |
| Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era L Tao, CA Clarke, AS Rosenberg, RH Advani, BA Jonas, CR Flowers, ... British journal of haematology 178 (1), 72-80, 2017 | 46 | 2017 |
| Second primary malignancies in multiple myeloma: A review C Poh, T Keegan, AS Rosenberg Blood reviews 46, 100757, 2021 | 45 | 2021 |
| Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center ME Tenold, BN Moskoff, DJ Benjamin, RT Hoeg, AS Rosenberg, M Abedi, ... Frontiers in oncology 11, 649209, 2021 | 40 | 2021 |
| Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor A Rosenberg, P Mathew Expert opinion on investigational drugs 22 (6), 787-794, 2013 | 40 | 2013 |
| Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma S Gupta, S Abouzaid, R Liebert, K Parikh, B Ung, AS Rosenberg Clinical Lymphoma Myeloma and Leukemia 18 (3), 210-218, 2018 | 33 | 2018 |
| Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance AS Rosenberg, A Brunson, JK Paulus, J Tuscano, T Wun, THM Keegan, ... Blood cancer journal 7 (9), e605-e605, 2017 | 33 | 2017 |
| Hodgkin lymphoma post‐transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival AS Rosenberg, AK Klein, R Ruthazer, AM Evens American journal of hematology 91 (6), 560-565, 2016 | 31 | 2016 |
| Blinatumomab/lenalidomide in relapsed/refractory non-Hodgkin's lymphoma: a phase i california cancer consortium study of safety, efficacy and immune correlative analysis C Poh, P Frankel, C Ruel, M Abedi, E Schwab, CL Costello, J Zain, ... Blood 134, 760, 2019 | 28 | 2019 |
| Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay AS Rosenberg, S Bainbridge, R Pahwa, I Jialal Clinical Biochemistry 49 (15), 1202-1204, 2016 | 28 | 2016 |
| A phase 1, first-in-human study of AMG 176, a selective MCL-1 inhibitor, in patients with relapsed or refractory multiple myeloma A Spencer, AS Rosenberg, A Jakubowiak, N Raje, M Chatterjee, S Trudel, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e53-e54, 2019 | 22 | 2019 |
| Association between autologous stem cell transplant and survival among Californians with multiple myeloma AS Rosenberg, A Brunson, BA Jonas, THM Keegan, T Wun JNCI: Journal of the National Cancer Institute 111 (1), 78-85, 2019 | 22 | 2019 |
| Incidence and evaluation of incidental abnormal bone marrow signal on magnetic resonance imaging GL Shah, AS Rosenberg, J Jarboe, A Klein, F Cossor The Scientific World Journal 2014, 2014 | 19 | 2014 |
| Impact of latency time on survival for adolescents and young adults with a second primary malignancy M Goldfarb, AS Rosenberg, Q Li, THM Keegan Cancer 124 (6), 1260-1268, 2018 | 18 | 2018 |
| Survival analyses and prognosis of plasma-cell myeloma and plasmacytoma-like posttransplantation lymphoproliferative disorders AS Rosenberg, R Ruthazer, JK Paulus, DM Kent, AM Evens, AK Klein Clinical Lymphoma Myeloma and Leukemia 16 (12), 684-692. e3, 2016 | 18 | 2016 |
Theresa KeeganUniversity of California, DavisVerified email at ucdavis.edu
